NSE - Delayed Quote • INR
Ipca Laboratories Limited (IPCALAB.NS)
At close: 3:30 PM GMT+5:30
Breakdown
TTM
3/31/2023
3/31/2022
3/31/2021
Total Revenue
71,461,900.00
62,068,500.00
57,664,600.00
53,660,000.00
Cost of Revenue
25,820,400.00
24,075,100.00
21,059,700.00
18,017,600.00
Gross Profit
45,641,500.00
37,993,400.00
36,604,900.00
35,642,400.00
Operating Expense
37,119,900.00
30,945,800.00
25,978,300.00
22,462,200.00
Operating Income
8,521,600.00
7,047,600.00
10,626,600.00
13,180,200.00
Net Non Operating Interest Income Expense
-506,500.00
311,600.00
229,700.00
246,800.00
Pretax Income
8,955,100.00
7,452,900.00
11,357,200.00
13,889,800.00
Tax Provision
2,881,400.00
2,533,600.00
2,247,700.00
2,401,400.00
Net Income Common Stockholders
5,642,800.00
4,713,200.00
8,840,800.00
11,400,100.00
Diluted NI Available to Com Stockholders
5,642,800.00
4,713,200.00
8,840,800.00
11,400,100.00
Basic EPS
22.25
18.58
34.85
45.01
Diluted EPS
22.25
18.58
34.85
45.01
Basic Average Shares
253,642.60
253,704.22
253,704.22
253,279.56
Diluted Average Shares
253,642.60
253,704.22
253,704.22
253,279.56
Rent Expense Supplemental
--
164,100.00
154,700.00
139,900.00
Total Expenses
62,940,300.00
55,020,900.00
47,038,000.00
40,479,800.00
Net Income from Continuing & Discontinued Operation
5,642,800.00
4,713,200.00
8,840,800.00
11,400,100.00
Normalized Income
5,007,696.80
4,544,028.73
8,810,882.03
11,478,675.50
Interest Income
--
793,500.00
341,700.00
369,500.00
Interest Expense
1,269,000.00
450,900.00
72,400.00
86,100.00
Net Interest Income
-506,500.00
311,600.00
229,700.00
246,800.00
EBIT
10,224,100.00
7,903,800.00
11,429,600.00
13,975,900.00
EBITDA
13,510,600.00
10,519,400.00
13,753,800.00
16,067,600.00
Reconciled Cost of Revenue
25,820,400.00
24,075,100.00
21,059,700.00
18,017,600.00
Reconciled Depreciation
3,286,500.00
2,615,600.00
2,324,200.00
2,091,700.00
Net Income from Continuing Operation Net Minority Interest
5,642,800.00
4,713,200.00
8,840,800.00
11,400,100.00
Total Unusual Items Excluding Goodwill
936,400.00
256,300.00
37,300.00
-95,000.00
Total Unusual Items
936,400.00
256,300.00
37,300.00
-95,000.00
Normalized EBITDA
12,574,200.00
10,263,100.00
13,716,500.00
16,162,600.00
Tax Rate for Calcs
0.00
0.00
0.00
0.00
Tax Effect of Unusual Items
301,296.80
87,128.73
7,382.03
-16,424.50
3/31/2021 - 1/1/1996
Upgrade to begin using 40 years of financial statements and get so much more.
Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.
UpgradeRelated Tickers
TORNTPHARM.NS Torrent Pharmaceuticals Limited
2,694.30
+0.29%
ALKEM.NS Alkem Laboratories Limited
4,867.65
+3.11%
DIVISLAB.NS Divi's Laboratories Limited
3,843.80
+0.79%
AUROPHARMA.NS Aurobindo Pharma Limited
1,103.40
+1.78%
GLENMARK.BO Glenmark Pharmaceuticals Limited
1,079.55
+0.77%
MEDICO.NS Medico Remedies Limited
46.75
-2.30%
LAURUSLABS.NS Laurus Labs Limited
425.90
-1.96%
GRANULES.NS Granules India Limited
417.95
-0.04%
ERIS.NS Eris Lifesciences Limited
883.60
+1.55%
DIVISLAB.BO Divi's Laboratories Limited
3,840.75
+0.64%